Gene Therapy CDMOs — Ranked by Signal Score · 2026
Gene Therapy manufacturers on CDMO Signal: 61 listed. 9 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Novartis (in-house manufacturer, Signal Score 85.4), Takeda (also makes its own products, Signal Score 83.4) and AGC Biologics (Signal Score 79.9). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
Gene Therapy CDMOs with the most regulatory evidence on file
Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.
The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.
FDA inspection outcomes across these CDMOs: 46 NAI (no action), 72 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (86), UNITED KINGDOM (55), Denmark (52), Austria (39), Germany (30).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 2 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 3 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 4 |
KB
|
84.1 | 98.5 | 2 insp · 1 GMP | 2026-04-01 · VAI | Limited | — |
| 5 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 6 |
TK
|
83.4 | 100.0 | 4 insp · 20 GMP | 2026-04-10 · NAI | — | 100 programs |
| 7 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 8 |
WB2
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | 2026-07-03 · VAI | — | — |
| 9 |
LB
|
81.6 | 100.0 | 2 insp · 0 GMP | 2026-09-18 · NAI | — | — |
| 10 |
NW
|
80.8 | 100.0 | 0 insp · 8 GMP | None on file | Available | — |
| 11 |
BR
|
80.3 | 97.2 | 6 insp · 10 GMP | 2026-05-13 · VAI | — | — |
| 12 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 13 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 14 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 15 |
UM
Boston, MA
|
78.7 | 96.7 | 2 insp · 0 GMP | 2025-12-18 · VAI | — | — |
| 16 |
GZ
|
78.1 | 100.0 | 1 insp · 0 GMP | 2025-08-27 · NAI | Available | — |
| 17 |
AA
Rockville, MD · Alachua, FL · Munich, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 18 |
NG
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 19 |
ET
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 20 |
PG
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 21 |
CE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 22 |
XP
Bristol, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 23 |
AD
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 24 |
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
|
77.6 | 93.2 | 19 insp · 10 GMP | 2026-06-30 · NAI | Available | 2 programs |
| 25 |
AG2
San Carlos, CA
|
77.6 | 98.8 | 1 insp · 0 GMP | 2025-04-18 · VAI | — | — |
| 26 |
VG
|
76.8 | 100.0 | 0 insp · 4 GMP | None on file | Available | — |
| 27 |
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
|
76.2 | 100.0 | 2 insp · 13 GMP | 2024-06-17 · NAI | Available | 7 programs |
| 28 |
|
76.1 | 77.3 | 24 insp · 39 GMP | 2026-05-22 · VAI Warning letter 2025-11-20 |
— | — |
| 29 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 30 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |
| 31 |
RT
|
71.1 | 100.0 | 0 insp · 4 GMP | None on file | — | 1 program |
| 32 |
EM
|
66.1 | — | — | None on file | — | 4 programs |
| 33 |
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
|
64.0 | — | — | None on file | — | — |
| 34 |
AN
Columbus, OH
|
63.0 | — | — | None on file | Available | — |
| 35 |
RA
Stockholm, Sweden
|
63.0 | — | — | None on file | — | — |
| 36 |
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
|
61.8 | — | — | None on file | — | 10 programs |
| 37 |
OB
Hamilton, ON
|
61.5 | — | 0 insp · 2 GMP | None on file | — | — |
| 38 |
GF
Alameda, CA and South San Francisco
|
61.5 | — | — | None on file | Available | — |
| 39 |
FB
|
61.2 | — | — | None on file | 3 programs | |
| 40 |
MA
College Station, TX
|
59.0 | — | — | None on file | Available | — |
| 41 |
VB
Philadelphia, PA
|
59.0 | — | — | None on file | — | — |
| 42 |
MS
Princeton, NJ
|
59.0 | — | — | None on file | — | — |
| 43 |
WB
Madison, WI
|
59.0 | — | — | None on file | — | — |
| 44 |
EB
|
59.0 | — | — | None on file | — | — |
| 45 |
VM
Cambridge, MA
|
59.0 | — | — | None on file | — | — |
| 46 |
AM
Gerenzano, Italy
|
59.0 | — | — | None on file | — | — |
| 47 |
HX
|
59.0 | — | — | None on file | — | — |
| 48 |
TR
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | None on file | — | 8 programs |
| 49 |
UB
|
56.5 | — | — | None on file | — | — |
| 50 |
CV
Cologne, Germany
|
56.5 | — | — | None on file | — | — |
| — |
Germany
|
Profiled | — | 2 insp · 2 GMP | 2023-09-08 · VAI | — | — |
| — |
Chongqing, China
|
Profiled | — | 1 insp · 0 GMP | 2024-03-29 · NAI | — | — |
| — |
|
Profiled | — | 3 insp · 0 GMP | 2025-10-29 · VAI | — | — |
| — |
San Diego, California, USA
|
Profiled | — | — | None on file | — | — |
What to evaluate in a Gene Therapy CDMO
Which vector platform does my gene therapy program need?
How does CDMO Signal aggregate gene therapy CDMOs?
Which gene therapy CDMOs cover multiple vector platforms?
How is gene therapy CDMO scoring different from generic biologics?
Gene Therapy CDMOs — Frequently Asked Questions
For a European shortlist, see the best gene therapy CDMO in Europe.